Birgit Reinhardt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Birgit Reinhardt has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
David Navarro
Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, Microbiology Service, Valencia, Spain
3 shared publicationsEstela Giménez
Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, Microbiology Service, Valencia, Spain
3 shared publicationsEliseo Albert
Hospital Clínico Universitario de Valencia , Valencia, Spain
2 shared publicationsMark M. Sasaki
Abbott Molecular Inc. , Des Plaines, Illinois, USA
2 shared publicationsTom Vreeswijk
Leiden University Medical Center , Leiden, The Netherlands
2 shared publicationsAna Marcos
Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, Microbiology Service, Valencia, Spain
1 shared publication
Latest Publications
- Open Access
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0030625
Analytical and clinical evaluation of the Alinity m Resp-4-Plex assay in comparison to two singleplex SARS-CoV-2 assays and one multiplex respiratory assay
After transition to the endemic phase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, multiplex molecular assays detecting SARS-CoV-2, influenza A (FluA) and B (FluB), and respiratory syncytial virus (RSV) are key to following international monitoring guidance, especially in future outbreak situations. In the present study, the analytical and clinical performance of the Alinity m Resp-4-Plex assay (“Alin4Plex”) was evaluated in comparison to those of three other assays: Alinity m SARS-CoV-2 (“AlinSARS”), RealTi m e SARS-CoV-2 (“RT-SARS”), and Allplex SARS-CoV-2/FluA/FluB/RSV (“Allplex”). Alin4Plex and AlinSARS exhibited 100% detection rates at 100 IU/mL, while RT-SARS and Allplex showed 90 and 40% at 200 IU/mL, respectively. Similarly, 100% detection rates by Alin4Plex were obtained at 100 (FluA, FluB) and 500 cp/mL (RSV) and by Allplex at 5,000 (FluB) and 10,000 cp/mL (RSV), with a 90% detection rate at 10,000 cp/mL (FluA). Retesting clinical specimens with 201, 198, 73, and 188 positive results for SARS-CoV-2, FluA, FluB, and RSV using Alin4Plex, the positivity rate by Allplex was considerably lower, with 119 (59%), 154 (78%), 42 (58%), and 91 positive specimens (48%), respectively, and decreased with increasing Ct values. Ct values correlated well between Alin4Plex and Allplex for SARS-CoV-2 and RSV ( r > 0.92), but correlation was only moderate for FluA and FluB ( r = 0.56 and 0.40, respectively). Overall, the multiplex assay Alin4Plex conducted on the high-throughput, random access Alinity m system exhibited high sensitivity for SARS-CoV-2, FluA, FluB, and RSV in a single test. It enables laboratories to rapidly scale up respiratory testing in future outbreak situations and provides valuable information for optimized patient management. IMPORTANCE: After the transition of the coronavirus disease 2019 (COVID-19) pandemic into an endemic phase, a rebound of transmissions of influenza A, influenza B, and respiratory syncytial virus (RSV) with the risk of severe morbidity and mortality has been observed. Overlapping symptoms complicate accurate diagnosis of respiratory infections and may delay adequate treatment. A multiplex PCR assay conducted on a random-access high-throughput automated platform enables accelerated and simultaneous detection of respiratory viruses, thus enhancing diagnostic efficiency, reducing the need for multiple tests, consolidating workflow, and enabling timely and appropriate patient care. This study evaluated the analytical and clinical performance of the Alinity m Resp-4-Plex assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A, influenza B, and RSV in comparison to other commercially available multiplex and singleplex tests. Results are crucial for identifying the most appropriate diagnostic method to improve patient outcome and optimize resource utilization in clinical settings.
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0030625
Open AccessAnalytical and clinical evaluation of the Alinity m Resp-4-Plex assay in comparison to two singleplex SARS-CoV-2 assays and one multiplex respiratory assay
After transition to the endemic phase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, multiplex molecular assays detecting SARS-CoV-2, influenza A (FluA) and B (FluB), and respiratory syncytial virus (RSV) are key to following international monitoring guidance, especially in future outbreak situations. In the present study, the analytical and clinical performance of the Alinity m Resp-4-Plex assay (“Alin4Plex”) was evaluated in comparison to those of three other assays: Alinity m SARS-CoV-2 (“AlinSARS”), RealTi m e SARS-CoV-2 (“RT-SARS”), and Allplex SARS-CoV-2/FluA/FluB/RSV (“Allplex”). Alin4Plex and AlinSARS exhibited 100% detection rates at 100 IU/mL, while RT-SARS and Allplex showed 90 and 40% at 200 IU/mL, respectively. Similarly, 100% detection rates by Alin4Plex were obtained at 100 (FluA, FluB) and 500 cp/mL (RSV) and by Allplex at 5,000 (FluB) and 10,000 cp/mL (RSV), with a 90% detection rate at 10,000 cp/mL (FluA). Retesting clinical specimens with 201, 198, 73, and 188 positive results for SARS-CoV-2, FluA, FluB, and RSV using Alin4Plex, the positivity rate by Allplex was considerably lower, with 119 (59%), 154 (78%), 42 (58%), and 91 positive specimens (48%), respectively, and decreased with increasing Ct values. Ct values correlated well between Alin4Plex and Allplex for SARS-CoV-2 and RSV ( r > 0.92), but correlation was only moderate for FluA and FluB ( r = 0.56 and 0.40, respectively). Overall, the multiplex assay Alin4Plex conducted on the high-throughput, random access Alinity m system exhibited high sensitivity for SARS-CoV-2, FluA, FluB, and RSV in a single test. It enables laboratories to rapidly scale up respiratory testing in future outbreak situations and provides valuable information for optimized patient management. IMPORTANCE: After the transition of the coronavirus disease 2019 (COVID-19) pandemic into an endemic phase, a rebound of transmissions of influenza A, influenza B, and respiratory syncytial virus (RSV) with the risk of severe morbidity and mortality has been observed. Overlapping symptoms complicate accurate diagnosis of respiratory infections and may delay adequate treatment. A multiplex PCR assay conducted on a random-access high-throughput automated platform enables accelerated and simultaneous detection of respiratory viruses, thus enhancing diagnostic efficiency, reducing the need for multiple tests, consolidating workflow, and enabling timely and appropriate patient care. This study evaluated the analytical and clinical performance of the Alinity m Resp-4-Plex assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A, influenza B, and RSV in comparison to other commercially available multiplex and singleplex tests. Results are crucial for identifying the most appropriate diagnostic method to improve patient outcome and optimize resource utilization in clinical settings.
- Open Access
- 2 July 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (7) , e0420123
Performance evaluation of the Alinity m system for quantifying cytomegalovirus DNA in samples of the respiratory, gastrointestinal, and urinary tract
Quantitation of cytomegalovirus (CMV) DNA load in specimens other than blood such as bronchoalveolar lavages, intestinal biopsies, or urine has become a common practice as an ancillary tool for the diagnosis of CMV pneumonitis, intestinal disease, or congenital infection, respectively. Nevertheless, most commercially available CMV PCR platforms have not been validated for CMV DNA detection in these specimen types. In this study, a laboratory-developed test based on Alinity m CMV (“Alinity LDT”) was evaluated. Reproducibility assessment using spiked bronchial aspirate (BAS) or urine samples showed low standard deviations of 0.08 and 0.27 Log IU/mL, respectively. Evaluating the clinical performance of Alinity LDT in comparison to a laboratory-developed test based on RealTi m e CMV (“RealTi m e LDT”) showed good concordance across 200 clinical specimens including respiratory specimens, intestinal biopsies, urine, and stool. A high Pearson's correlation coefficient of r = 0.92, a low mean bias of −0.12 Log IU/mL, a good qualitative agreement of 90%, and a Cohen's kappa value of 0.76 (substantial agreement) were observed. In separate analyses of the sample types BAS, tracheal aspirates, bronchoalveolar lavage, biopsies, and urine, the assay results correlated well between the two platforms with r values between 0.88 and 0.99 and a bias m e LDT in respiratory, gastrointestinal, and urine samples and may enhance patient management with rapid result reporting. IMPORTANCE: In transplant recipients, a major cause for morbidity and mortality is end-organ disease by primary or secondary CMV infection of the respiratory or gastrointestinal tract. In addition, sensorineural hearing loss and neurodevelopmental abnormalities are frequent sequelae of congenital CMV infections in newborns. Standard of care for highly sensitive detection and quantitation of the CMV DNA load in plasma and whole blood specimens is real-time PCR testing. Beyond that, there is a need for quantitative determination of CMV DNA levels in respiratory, gastrointestinal, and urinary tract specimens using a highly automated, random access CMV PCR assay with a short turnaround time to enable early diagnosis and treatment. In the present study, clinical performance of the fully automated Alinity m analyzer in comparison to the current RealTi m e LDT assay was evaluated in eight different off-label sample types.
- 2 July 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (7) , e0420123
Open AccessPerformance evaluation of the Alinity m system for quantifying cytomegalovirus DNA in samples of the respiratory, gastrointestinal, and urinary tract
Quantitation of cytomegalovirus (CMV) DNA load in specimens other than blood such as bronchoalveolar lavages, intestinal biopsies, or urine has become a common practice as an ancillary tool for the diagnosis of CMV pneumonitis, intestinal disease, or congenital infection, respectively. Nevertheless, most commercially available CMV PCR platforms have not been validated for CMV DNA detection in these specimen types. In this study, a laboratory-developed test based on Alinity m CMV (“Alinity LDT”) was evaluated. Reproducibility assessment using spiked bronchial aspirate (BAS) or urine samples showed low standard deviations of 0.08 and 0.27 Log IU/mL, respectively. Evaluating the clinical performance of Alinity LDT in comparison to a laboratory-developed test based on RealTi m e CMV (“RealTi m e LDT”) showed good concordance across 200 clinical specimens including respiratory specimens, intestinal biopsies, urine, and stool. A high Pearson's correlation coefficient of r = 0.92, a low mean bias of −0.12 Log IU/mL, a good qualitative agreement of 90%, and a Cohen's kappa value of 0.76 (substantial agreement) were observed. In separate analyses of the sample types BAS, tracheal aspirates, bronchoalveolar lavage, biopsies, and urine, the assay results correlated well between the two platforms with r values between 0.88 and 0.99 and a bias m e LDT in respiratory, gastrointestinal, and urine samples and may enhance patient management with rapid result reporting. IMPORTANCE: In transplant recipients, a major cause for morbidity and mortality is end-organ disease by primary or secondary CMV infection of the respiratory or gastrointestinal tract. In addition, sensorineural hearing loss and neurodevelopmental abnormalities are frequent sequelae of congenital CMV infections in newborns. Standard of care for highly sensitive detection and quantitation of the CMV DNA load in plasma and whole blood specimens is real-time PCR testing. Beyond that, there is a need for quantitative determination of CMV DNA levels in respiratory, gastrointestinal, and urinary tract specimens using a highly automated, random access CMV PCR assay with a short turnaround time to enable early diagnosis and treatment. In the present study, clinical performance of the fully automated Alinity m analyzer in comparison to the current RealTi m e LDT assay was evaluated in eight different off-label sample types.
- Open Access
- 24 October 2023
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 61 (10) , e0041523
Multicenter performance evaluation of the Alinity m CMV assay for quantifying cytomegalovirus DNA in plasma samples
Monitoring of cytomegalovirus (CMV) viral load is critical for informing treatment decisions in order to prevent the severe health consequences of CMV infection or reactivation of latent CMV in immunocompromised individuals. This first field evaluation examined the analytical and clinical performance of the Alinity m CMV assay. Analytical performance was assessed with a commercially available six-member panel, while the clinical performance evaluation compared the Alinity m CMV assay to the RealTi m e CMV assay and a laboratory-developed test (LDT) as the test of record at three large hospital-based clinical laboratories. Precision of the Alinity m CMV assay was demonstrated with total standard deviation (SD) between 0.08 and 0.28 Log IU/mL. A total of 457 plasma specimens were tested on the Alinity m CMV assay and compared to the test of record at each site ( n = 304 with RealTi m e CMV and n = 153 with LDT CMV). The Alinity m CMV assay had excellent correlation (correlation coefficient r ≥0.942) in comparison to the RealTi m e CMV or LDT CMV assays. The mean observed bias ranged from −0.03 to 0.34 Log IU/mL. Median onboard turnaround time of Alinity m CMV was less than 3 h. When the CMV assay is run on the Alinity m system, it has the capacity to shorten time to result and, therefore, to therapy.
- 24 October 2023
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 61 (10) , e0041523
Open AccessMulticenter performance evaluation of the Alinity m CMV assay for quantifying cytomegalovirus DNA in plasma samples
Monitoring of cytomegalovirus (CMV) viral load is critical for informing treatment decisions in order to prevent the severe health consequences of CMV infection or reactivation of latent CMV in immunocompromised individuals. This first field evaluation examined the analytical and clinical performance of the Alinity m CMV assay. Analytical performance was assessed with a commercially available six-member panel, while the clinical performance evaluation compared the Alinity m CMV assay to the RealTi m e CMV assay and a laboratory-developed test (LDT) as the test of record at three large hospital-based clinical laboratories. Precision of the Alinity m CMV assay was demonstrated with total standard deviation (SD) between 0.08 and 0.28 Log IU/mL. A total of 457 plasma specimens were tested on the Alinity m CMV assay and compared to the test of record at each site ( n = 304 with RealTi m e CMV and n = 153 with LDT CMV). The Alinity m CMV assay had excellent correlation (correlation coefficient r ≥0.942) in comparison to the RealTi m e CMV or LDT CMV assays. The mean observed bias ranged from −0.03 to 0.34 Log IU/mL. Median onboard turnaround time of Alinity m CMV was less than 3 h. When the CMV assay is run on the Alinity m system, it has the capacity to shorten time to result and, therefore, to therapy.
- Open Access
- 24 October 2023
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 61 (10) , e0047223
Multi-site performance evaluation of the Alinity m Molecular assay for quantifying Epstein-Barr virus DNA in plasma samples
Detection and monitoring of acute infection or reactivation of Epstein-Barr virus (EBV) are critical for treatment decision-making and to reduce the risk of EBV-related malignancies and other associated diseases in immunocompromised individuals. The analytical and clinical performance of the Alinity m EBV assay was evaluated at two independent study sites; analytical performance was assessed by evaluating precision with a commercially available 5-member EBV verification panel, while the clinical performance of the Alinity m EBV assay was compared to the RealTi me EBV assay and a laboratory-developed test (LDT) as the routine test of record (TOR). Analytical analysis demonstrated standard deviation (SD) between 0.08 and 0.13 Log IU/mL. A total of 300 remnant plasma specimens were retested with the Alinity m EBV assay, and results were compared to those of the TOR at the respective study sites ( n = 148 with the RealTi m e EBV assay and n = 152 with the LDT EBV assay). Agreement between Alinity m EBV and RealTi m e EBV or LDT EBV assays had kappa values of 0.88 and 0.84, respectively, with correlation coefficients r of 0.956 and 0.912, while the corresponding observed mean bias was −0.02 and −0.19 Log IU/mL. The Alinity m EBV assay had a short median onboard turnaround time of 2:40 h. Thus, the Alinity m system can shorten the time to results and, therefore, to therapy.
- 24 October 2023
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 61 (10) , e0047223
Open AccessMulti-site performance evaluation of the Alinity m Molecular assay for quantifying Epstein-Barr virus DNA in plasma samples
Detection and monitoring of acute infection or reactivation of Epstein-Barr virus (EBV) are critical for treatment decision-making and to reduce the risk of EBV-related malignancies and other associated diseases in immunocompromised individuals. The analytical and clinical performance of the Alinity m EBV assay was evaluated at two independent study sites; analytical performance was assessed by evaluating precision with a commercially available 5-member EBV verification panel, while the clinical performance of the Alinity m EBV assay was compared to the RealTi me EBV assay and a laboratory-developed test (LDT) as the routine test of record (TOR). Analytical analysis demonstrated standard deviation (SD) between 0.08 and 0.13 Log IU/mL. A total of 300 remnant plasma specimens were retested with the Alinity m EBV assay, and results were compared to those of the TOR at the respective study sites ( n = 148 with the RealTi m e EBV assay and n = 152 with the LDT EBV assay). Agreement between Alinity m EBV and RealTi m e EBV or LDT EBV assays had kappa values of 0.88 and 0.84, respectively, with correlation coefficients r of 0.956 and 0.912, while the corresponding observed mean bias was −0.02 and −0.19 Log IU/mL. The Alinity m EBV assay had a short median onboard turnaround time of 2:40 h. Thus, the Alinity m system can shorten the time to results and, therefore, to therapy.